GDTC

CytoMed Therapeutics Limited

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$0.84

Price (1 Year)

$1.84 $0.78

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %1.1 / %30
Non-compliant assets / Total market cap %0 / %30
Non-compliant revenue / Total income %27.6 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.

Website

Analysis (Turkish): GDTC Hissesi Caiz mi, Helal mi? CytoMed Therapeutics Limited Katılım Analizi